Cita APA

Lozano, R., Lorente, D., Aragon, I. M., Romero-Laorden, N., Nombela, P., & Mateo Valderrama, J. (2021). Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.

Citación estilo Chicago

Lozano, Rebeca, David Lorente, Isabel M. Aragon, Nuria Romero-Laorden, Paz Nombela, y Joaquim Mateo Valderrama. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. 2021.

Cita MLA

Lozano, Rebeca, et al. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. 2021.